Immune Health Supplements Market Size to Worth Around USD 136.0 Bn by 2030

The global Immune Health Supplements  market is expected to grow at a CAGR of around 13.2% over the forecast period 2021 to 2030 and expected to reach the market value of around US$ 136.0 billion by 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38603

Growth Factors

 The growing prevalence of various infectious diseases caused by several micro-organisms, such as bacteria, fungi, viruses, and parasites, coupled with the rising demand for supplements to increase the body’s immune system, is expected to boost the immune health supplements adoption across the globe. Besides, increasing adoption of immunity-boosting products due to the COVID-19 pandemic is also anticipated to accelerate the market growth over the forecast years. According to the Council for Responsible Nutrition (CRN) report in 2020, the consumption of dietary supplements among Americans was about 73 percent. growth include the increasing prevalence of infectious diseases, diabetes, and several other disorders due to lack of immunity. In recent years, there is a constant trend observed about the increase in supplement usage to improve the body’s immunity all over the globe.

Report Coverage

Report Scope	Details
Market Size	USD 136.0 billion by 2030
Growth Rate	CAGR of 13.2% From 2021 to 2030
Base Year	2021
Historic Data	2017 to 2020
Forecast Period	2021 to 2030
Segments Covered	Product, form, Application, Mode of Medication, Distribution Channel
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned	Bayer AG; Pfizer Inc.; Sun Pharmaceutical Industries Limited; Swisse Wellness Pty Ltd; GlaxoSmithKline Inc.; Abbott Laboratories; Amway Corp.; The Nature’s Bounty Co.; Herbalife Nutrition of America, Inc.; Himalaya Global Holdings Ltd.; American Health; Unilever; Sanofi; Novartis; Boehringer Ingelheim; Nestlè; Danone

Report Highlights

 The vitamin and mineral supplement segment dominated the market and accounted for the largest revenue share of 64.5% in 2020. Increasing preference for supplements among consumers across the globe to boost their immunity is driving the segment. The proven health benefits and wide availability of vitamin C, D, B complex, multivitamins, and the minerals, such as zinc and selenium, in supporting the immune system propelling the segment growth. Vitamin C sales seem to be higher after the COVID-19 pandemic all over the globe.

The herbal supplement segment is expected to witness a CAGR of over 12.0% during the forecast period. High demand among consumers to use herbel supplements over nutraceuticals to enhance the body’s immune health without any side effects driving the segment.

The tablet segment dominated the market and accounted for the largest revenue share of 34.8% in 2020. Most of the vendors are manufacturing supplements in tablet formulation due to their higher shelf life, low cost, and higher convenience. The softgels segment is expected to exhibit the highest CAGR of 13.4 % over the forecast period. This growth is attributed to the easy route of administration offered by the gels to consume vitamins and minerals.

The respiratory tract infection segment dominated the market and accounted for the largest revenue share of 38.8% in 2020. The demand for the use of immune health supplements has been showing off an extraordinary growth since the COVID19 pandemic.The gut health segment is anticipated to become the second-highest revenue contributor to the market over the forecast period. Many studies reported that the gut microbiome plays an important role to maintain the body’s innate and adaptive immunity.

The self-medication segment dominated the market and accounted for the highest revenue share of 69.5% in 2020. The supplements for boosting immunity do not require a prescription to purchase from a drug store, which is anticipated to provide the highest revenue share for this segment by mode of medication and its trend is expected to continue over the forecast years.

The pharmacies/drug stores segment dominated the market and accounted for the largest revenue share of 60.9% in 2020. Rising consumer preference and availability of a wide variety of products is expected to augment the highest sale of the products in pharmacies or drug stores.

the e-commerce segment is expected to witness a CAGR of 15.1% over the forecast period owing to the growing usage of e-commerce channels to purchase supplements. Furthermore, a rapid increase in the number of e-commerce vendors due to the COVID-19 pandemic is also expected to drive the segment over the forecast period.

North America dominated the market and accounted for the largest revenue share of 40.1% in 2020. The highest consumer base for immune health supplements and growing awareness among the individuals are the factors anticipated to fuel the regional growth in the immune health supplements market over the forecast years.

the market is also estimated to witness the fastest CAGR of 15.8% during the forecast period. Growing per capita income, increasing consumer base in Asian countries such as China, India, and South Korea is anticipated to drive the demand for immune health supplements in these regions over the forecast years.

Key Players

• Bayer AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Swisse Wellness Pty Ltd.
• GlaxoSmithKline Inc.
• Abbott Laboratories
• Amway Corp.
• The Nature’s Bounty Co.
• Herbalife Nutrition of America, Inc.
• Himalaya Global Holdings Ltd.
• American Health
• Unilever
• Sanofi
• Novartis
• Boehringer Ingelheim
• Nestlè
• Danone

Market Segmentation

• Product
  • Vitamin and Mineral Supplements
    • Vitamin C Supplements
    • Vitamin D Supplements
    • Vitamin B complex Supplements
    • Multivitamins
    • Selenium Supplements
    • Zinc Supplements
    • Others
  • Herbal Supplements
  • Probiotic Supplements
  • Others
• Form
  • Capsules
  • Tablets
  • Powder
  • Liquid
  • Gel
  • Soft gels
  • Others
• Application
  • Hair growth
  • Gut health
  • Respiratory tract infection
  • Others
• Mode Of Medication
  • Prescription based
  • Self-medication
• Distribution Channel
  • Pharmacies/Drug Stores
  • Supermarkets and Hypermarkets
  • E-commerce
  • Others
• Regional
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Singapore
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38603

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Immune Health Supplements Market, By Product

7.1.  Immune Health Supplements Market, by Product, 2021-2030

7.1.1.    Vitamin and Mineral Supplements

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Herbal Supplements

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Probiotic Supplements

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Others

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Immune Health Supplements Market, By Form

8.1.  Immune Health Supplements Market, by Form, 2021-2030

8.1.1.    Capsules

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Tablets

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Powder

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Liquid

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Gel

8.1.5.1.        Market Revenue and Forecast (2017-2030)

8.1.6.    Soft gels

8.1.6.1.        Market Revenue and Forecast (2017-2030)

8.1.7.    Others

8.1.7.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Immune Health Supplements Market, By Application

9.1.  Immune Health Supplements Market, by Application, 2021-2030

9.1.1.    Hair growth

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Gut health

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Respiratory tract infection

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Others

9.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Immune Health Supplements Market, By Mode Of Medication

10.1.        Immune Health Supplements Market, by Mode Of Medication, 2021-2030

10.1.1.  Prescription based

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Self-medication

10.1.2.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Immune Health Supplements Market, By Distribution Channel

11.1.        Immune Health Supplements Market, by Distribution Channel, 2021-2030

11.1.1.  Pharmacies/Drug Stores

11.1.1.1.      Market Revenue and Forecast (2017-2030)

11.1.2.  Supermarkets and Hypermarkets

11.1.2.1.      Market Revenue and Forecast (2017-2030)

11.1.3.  E-commerce

11.1.3.1.      Market Revenue and Forecast (2017-2030)

11.1.4.  Others

11.1.4.1.      Market Revenue and Forecast (2017-2030)

Chapter 12.      Global Immune Health Supplements  Market, Regional Estimates and Trend Forecast

12.1.        North America

12.1.1.  Market Revenue and Forecast, by Product (2017-2030)

12.1.2.  Market Revenue and Forecast, by Form (2017-2030)

12.1.3.  Market Revenue and Forecast, by Application (2017-2030)

12.1.4.  Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.1.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.6.  U.S.

12.1.6.1.      Market Revenue and Forecast, by Product (2017-2030)

12.1.6.2.      Market Revenue and Forecast, by Form (2017-2030)

12.1.6.3.      Market Revenue and Forecast, by Application (2017-2030)

12.1.6.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.1.6.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.1.7.  Rest of North America

12.1.7.1.      Market Revenue and Forecast, by Product (2017-2030)

12.1.7.2.      Market Revenue and Forecast, by Form (2017-2030)

12.1.7.3.      Market Revenue and Forecast, by Application (2017-2030)

12.1.7.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.1.7.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.        Europe

12.2.1.  Market Revenue and Forecast, by Product (2017-2030)

12.2.2.  Market Revenue and Forecast, by Form (2017-2030)

12.2.3.  Market Revenue and Forecast, by Application (2017-2030)

12.2.4.  Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.2.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.6.  UK

12.2.6.1.      Market Revenue and Forecast, by Product (2017-2030)

12.2.6.2.      Market Revenue and Forecast, by Form (2017-2030)

12.2.6.3.      Market Revenue and Forecast, by Application (2017-2030)

12.2.6.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.2.6.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.7.  Germany

12.2.7.1.      Market Revenue and Forecast, by Product (2017-2030)

12.2.7.2.      Market Revenue and Forecast, by Form (2017-2030)

12.2.7.3.      Market Revenue and Forecast, by Application (2017-2030)

12.2.7.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.2.7.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.8.  France

12.2.8.1.      Market Revenue and Forecast, by Product (2017-2030)

12.2.8.2.      Market Revenue and Forecast, by Form (2017-2030)

12.2.8.3.      Market Revenue and Forecast, by Application (2017-2030)

12.2.8.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.2.8.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.2.9.  Rest of Europe

12.2.9.1.      Market Revenue and Forecast, by Product (2017-2030)

12.2.9.2.      Market Revenue and Forecast, by Form (2017-2030)

12.2.9.3.      Market Revenue and Forecast, by Application (2017-2030)

12.2.9.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.2.9.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.        APAC

12.3.1.  Market Revenue and Forecast, by Product (2017-2030)

12.3.2.  Market Revenue and Forecast, by Form (2017-2030)

12.3.3.  Market Revenue and Forecast, by Application (2017-2030)

12.3.4.  Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.3.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.6.  India

12.3.6.1.      Market Revenue and Forecast, by Product (2017-2030)

12.3.6.2.      Market Revenue and Forecast, by Form (2017-2030)

12.3.6.3.      Market Revenue and Forecast, by Application (2017-2030)

12.3.6.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.3.6.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.7.  China

12.3.7.1.      Market Revenue and Forecast, by Product (2017-2030)

12.3.7.2.      Market Revenue and Forecast, by Form (2017-2030)

12.3.7.3.      Market Revenue and Forecast, by Application (2017-2030)

12.3.7.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.3.7.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.8.  Japan

12.3.8.1.      Market Revenue and Forecast, by Product (2017-2030)

12.3.8.2.      Market Revenue and Forecast, by Form (2017-2030)

12.3.8.3.      Market Revenue and Forecast, by Application (2017-2030)

12.3.8.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.3.8.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.3.9.  Rest of APAC

12.3.9.1.      Market Revenue and Forecast, by Product (2017-2030)

12.3.9.2.      Market Revenue and Forecast, by Form (2017-2030)

12.3.9.3.      Market Revenue and Forecast, by Application (2017-2030)

12.3.9.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.3.9.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.        MEA

12.4.1.  Market Revenue and Forecast, by Product (2017-2030)

12.4.2.  Market Revenue and Forecast, by Form (2017-2030)

12.4.3.  Market Revenue and Forecast, by Application (2017-2030)

12.4.4.  Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.4.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.6.  GCC

12.4.6.1.      Market Revenue and Forecast, by Product (2017-2030)

12.4.6.2.      Market Revenue and Forecast, by Form (2017-2030)

12.4.6.3.      Market Revenue and Forecast, by Application (2017-2030)

12.4.6.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.4.6.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.7.  North Africa

12.4.7.1.      Market Revenue and Forecast, by Product (2017-2030)

12.4.7.2.      Market Revenue and Forecast, by Form (2017-2030)

12.4.7.3.      Market Revenue and Forecast, by Application (2017-2030)

12.4.7.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.4.7.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.8.  South Africa

12.4.8.1.      Market Revenue and Forecast, by Product (2017-2030)

12.4.8.2.      Market Revenue and Forecast, by Form (2017-2030)

12.4.8.3.      Market Revenue and Forecast, by Application (2017-2030)

12.4.8.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.4.8.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.4.9.  Rest of MEA

12.4.9.1.      Market Revenue and Forecast, by Product (2017-2030)

12.4.9.2.      Market Revenue and Forecast, by Form (2017-2030)

12.4.9.3.      Market Revenue and Forecast, by Application (2017-2030)

12.4.9.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.4.9.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.        Latin America

12.5.1.  Market Revenue and Forecast, by Product (2017-2030)

12.5.2.  Market Revenue and Forecast, by Form (2017-2030)

12.5.3.  Market Revenue and Forecast, by Application (2017-2030)

12.5.4.  Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.5.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.6.  Brazil

12.5.6.1.      Market Revenue and Forecast, by Product (2017-2030)

12.5.6.2.      Market Revenue and Forecast, by Form (2017-2030)

12.5.6.3.      Market Revenue and Forecast, by Application (2017-2030)

12.5.6.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.5.6.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

12.5.7.  Rest of LATAM

12.5.7.1.      Market Revenue and Forecast, by Product (2017-2030)

12.5.7.2.      Market Revenue and Forecast, by Form (2017-2030)

12.5.7.3.      Market Revenue and Forecast, by Application (2017-2030)

12.5.7.4.      Market Revenue and Forecast, by Mode Of Medication (2017-2030)

12.5.7.5.      Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 13.  Company Profiles

13.1.              Bayer AG

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.              Pfizer Inc.

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.              Sun Pharmaceutical Industries Limited

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.              Swisse Wellness Pty Ltd.

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.              GlaxoSmithKline Inc.

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.              Abbott Laboratories

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.              Amway Corp.

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.              The Nature’s Bounty Co.

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.              Herbalife Nutrition of America, Inc.

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.           Himalaya Global Holdings Ltd.

13.10.1.               Company Overview

13.10.2.               Product Offerings

13.10.3.               Financial Performance

13.10.4.               Recent Initiatives

13.11.           American Health

13.11.1.               Company Overview

13.11.2.               Product Offerings

13.11.3.               Financial Performance

13.11.4.               Recent Initiatives

13.12.           Unilever

13.12.1.               Company Overview

13.12.2.               Product Offerings

13.12.3.               Financial Performance

13.12.4.               Recent Initiatives

13.13.           Sanofi

13.13.1.               Company Overview

13.13.2.               Product Offerings

13.13.3.               Financial Performance

13.13.4.               Recent Initiatives

13.14.           Novartis

13.14.1.               Company Overview

13.14.2.               Product Offerings

13.14.3.               Financial Performance

13.14.4.               Recent Initiatives

13.15.           Boehringer Ingelheim

13.15.1.               Company Overview

13.15.2.               Product Offerings

13.15.3.               Financial Performance

13.15.4.               Recent Initiatives

13.16.           Nestlè

13.16.1.               Company Overview

13.16.2.               Product Offerings

13.16.3.               Financial Performance

13.16.4.               Recent Initiatives

Chapter 14.  Research Methodology

14.1.              Primary Research

14.2.              Secondary Research

14.3.              Assumptions

Chapter 15.  Appendix

15.1.              About Us

15.2.              Glossary of Terms

Buy this Research Report study@https://www.visionresearchreports.com/report/cart/38603

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com